YIH
TSHA icon

Y-Intercept (HK)’s Taysha Gene Therapies TSHA Stock Holding History

Y-Intercept (HK)’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,486
Closed -$51.3K – 2174
2026
Q1 		$51.3K Buy
+11,486
New +$53.4K ﹤0.01% 1480
2025
Q2 		– Sell
-83,864
Closed -$117K – 2022
2025
Q1 		$117K Buy
+83,864
New +$140K 0.01% 1103
2024
Q2 		– Sell
-97,054
Closed -$279K – 1926
2024
Q1 		$279K Buy
+97,054
New +$202K 0.02% 988

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Y-Intercept (HK)'s TSHA Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 11,486 shares — an estimated $51.3K sold.

Y-Intercept (HK) first reported a position in TSHA in Q1 2024 and held it in 3 quarters. The position peaked at $279K in Q1 2024. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 11,486 Taysha Gene Therapies shares in Q2 2026, an estimated $51.3K.
  • Y-Intercept (HK) first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 3 quarters.
  • Y-Intercept (HK)'s Taysha Gene Therapies position peaked at $279K in Q1 2024.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.